ArticleCells2019
Angiogenic Potential of Bone Marrow Derived CD133
Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Prominosomes - a particular class of extracellular vesicles containing prominin-1/CD133?Journal of nanobiotechnology · 2025Review
- CD52/FLAG and CD52/HA Fusion Proteins as Novel Magnetic Cell Selection Markers.International journal of molecular sciences · 2024Article
- Narrative Review of Mesenchymal Stem Cell Therapy in Renal Diseases: Mechanisms, Clinical Applications, and Future Directions.Stem cells international · 2024Review
- Interaction between Mesenchymal Stem Cells and Immune Cells during Bone Injury Repair.International journal of molecular sciences · 2023Review
- Article
- New Approaches in Heart Research: Prevention Instead of Cardiomyoplasty?International journal of molecular sciences · 2023Review
- Cell-Free Treatments: A New Generation of Targeted Therapies for Treatment of Ischemic Heart Disease.Cell journal · 2022Article
- Stem Cell Studies in Cardiovascular Biology and Medicine: A Possible Key Role of Macrophages.Biology · 2022Review
- NFĸB Targeting in Bone Marrow Mesenchymal Stem Cell-Mediated Support of Age-Linked Hematological Malignancies.Stem cell reviews and reports · 2021Article
- Nucleated red blood cells participate in myocardial regeneration in the toadExperimental biology and medicine (Maywood, N.J.) · 2021Article
- Cellular Senescence Affects Cardiac Regeneration and Repair in Ischemic Heart Disease.Aging and disease · 2021Review
- Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy.Stem cell research & therapy · 2021Article
- Autophagy stimulation delayed biological aging and decreased cardiac differentiation in rabbit mesenchymal stem cells.Journal of cardiovascular and thoracic research · 2021Article
- Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives.Frontiers in cell and developmental biology · 2021Review
- COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?Journal of extracellular vesicles · 2020Review
- Motivating role of type H vessels in bone regeneration.Cell proliferation · 2020Review
- Dose-Independent Therapeutic Benefit of Bone Marrow Stem Cell Transplantation after MI in Mice.Biomedicines · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone marrow (BM)-derived stem cells with their various functions and characteristics have become a well-recognized source for the cell-based therapies. However, knowledge on their therapeutic potential and the shortage for a cross-link between distinct BM-derived stem cells, primed after the onset of myocardial infarction (MI), seems to be still rudimentary. Therefore, the post-examination of the therapeutic characteristics of such primed hematopoietic CD133 METHODS AND
resultsThe effects of respective CD133
conclusionThe interactions between CD271
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.